statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanguard Group Inc. cut its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 0.9% during the third quarter, according to its most recent 13F filing with the Securities and...

Vanguard Group Inc. Trims Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

This indicator may be signaling that AGIO's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Agios Pharmaceuticals (AGIO, $31.35) entered Downtrend as Momentum indicator drops below 0 level on Mar 08, 2024

This is a Bearish indicator signaling AGIO's price could decline from here. Traders may explore shorting the stock or put options...

Agios Pharmaceuticals (AGIO, $31.37) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 7, 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

This is a signal that AGIO's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Agios Pharmaceuticals (AGIO, $32.32) RSI Indicator left the overbought zone on February 29, 2024

Agios Pharmaceuticals (NASDAQ:AGIO  Get Free Report) had its price objective lowered by JPMorgan Chase  Co. from $31.00 to $30.00 in a research report issued to clients and investors on...

Agios Pharmaceuticals (NASDAQ:AGIO) PT Lowered to $30.00

Agios Pharmaceuticals (AGIO, $29.77) RSI Indicator left the overbought zone on February 22, 2024

CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

Agios Pharmaceuticals (AGIO, $26.8) RSI Indicator left the overbought zone on February 21, 2024

Agios Pharmaceuticals (AGIO, $27.11) RSI Indicator left the overbought zone on February 20, 2024

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Volume	391,760.00
52-Wk High	$35.50
52-Wk Low	$19.80

Period	Estimated	Reported	Surprise	Result
Q2'24	-$1.66	--	--	N/A
Q1'24	-$1.65	-$1.45	12.00%	BEAT
Q4'23	-$1.66	-$1.71	-3.19%	MISSED
Q3'23	-$1.70	-$1.64	3.67%	BEAT
Q2'23	-$1.56	-$1.51	3.28%	BEAT

AGIO Agios Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals